Metrion Adds to Board of Directors

Metrion Biosciences has appointed Dr. Barry Kenny and Dr. Andrew Southan to its Board of Directors. The appointments have been made to strengthen the focus on commercial and business development capabilities.

Dr. Kenny is chief business officer of Heptares Therapeutics. He was previously vice president, Drug Discovery at Takeda Cambridge, and commercial director at Paradigm Therapeutics. 

Dr. Southan joined Metrion as head of Commercial Operations in October 2016, and was promoted to chief operating officer in April 2017.  He has over 25 years of experience in ion channel research and development, starting his career at Wyeth Research (UK), followed by postdoctoral studies at Imperial College London. 

 Dr. Keith McCullagh, non-executive chairman, Metrion Biosciences, said, “I am delighted to welcome both Barry and Andy to Metrion’s Board of Directors. Barry Kenny’s substantial experience of drug discovery deal-making will be of great value to Metrion as we continue to build our worldwide CRO and collaboration business. Andy’s dedication to Metrion’s client service and quality of operations has been a major factor in the growth of the business, and his promotion to the Board signals our determination to continue to be the highest quality supplier in our field.”